Regulatory Telomir seeks FDA approval for Telomir-1 to treat breast cancer Pharmaceutical TechnologyTelomir Pharmaceuticals has submitted an IND application to the FDA for Telomir-1, its lead candidate targeting advanced and metastatic TNBC.RegulatoryOncologyRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaceutical Technology Telomir Pharmaceuticals has submitted an IND application to the FDA for Telomir-1, its lead candidate targeting advanced and metastatic TNBC. RegulatoryOncologyRead full story Post navigation Previous: ACC 2026: Sotatercept shows signal in CpcPH-HFpEF at lower doseNext: Symeres and Ambagon collaborate for colorectal cancer molecules Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
